Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

July 27th 2017

Genetic Tests Can Predict Tumor Aggressiveness and Help Treatment Decisions

Alison Rodriguez

Study used gene biomarker to identify which patients with colon cancer would not benefit from chemotherapy.

July 26th 2017

NCI Panel Discusses Importance of Research on Cancer Survivorship

Christina Mattina

During a panel hosted by the National Cancer Institute (NCI), patient advocates and survivorship experts discussed the strides made in the field of cancer survivorship research.

July 25th 2017

Mechanism for Checkpoint Inhibitor Resistance Identified in Invasive Bladder Cancer

Christina Mattina

Researchers have identified a cellular signaling pathway that when activated by mutations may prevent immune cells from infiltrating bladder tumors, thus making the cancer resistant to immune checkpoint inhibitors.

July 25th 2017

Cost-Effectiveness of a Patient Navigation Program to Improve Cervical Cancer Screening

Yan Li, PhD Erin Carlson, DrPH Roberto Villarreal, MD Leah Meraz, MA José A. Pagán, PhD

This study investigates the cost-effectiveness of a community-based patient navigation program to improve cervical cancer screening.

July 25th 2017

Low-Fat Dietary Patterns Potentially Linked to Lower Breast Cancer Mortality Rate

Alison Rodriguez

The Women’s Health Initiative Dietary Modification Trial examined the long-term influence of low-fat eating patterns on the breast cancer mortality rate.

July 25th 2017

Barriers to Recruiting ED Patients With Advanced Cancer for Palliative Care

Surabhi Dangi-Garimella, PhD

Patient refusal, symptom burden, and diagnostic disparities were identified as some of the most common barriers encountered when recruiting patients with advanced cancer for palliative treatment in the emergency department (ED).

July 25th 2017

Immune-Cell Numbers Determine Combination Immunotherapy Response in Melanoma Patients

Alison Rodriguez

The Journal of Clinical Investigation Insight recently published a study that analyzed 112 different melanoma tumors in attempt to correlate partially exhausted cytotoxic lymphocytes (peCTLs) and regulatory T lymphocyte (Treg) levels with response to combination immunotherapy.

July 24th 2017

Study of 1.7 Million Patients Finds Strong Link Between Teenage Obesity, Colon Cancer Risk

Mary Caffrey

Being overweight or obese as a teenager raises the risk of developing colon cancer later in life, a new study in the journal CANCER has found.

July 24th 2017

Kite's CAR-T Therapy Produces Durable Remission in DLBCL, Study Finds

Christina Mattina

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

July 22nd 2017

SEER-Medicare Database Analysis Notes Higher Resource Utilization Among Patients With Neuroendocrine Tumors

Surabhi Dangi-Garimella, PhD

In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine tumors to analyze their resource utilization.

July 22nd 2017

Brazilian Study Queries: Is NGS Cost-Effective in Advanced Lung Cancer?

Surabhi Dangi-Garimella, PhD

In a study presented at the 2017 American Society of Clinical Oncology Annual Metting, researchers from the Brazilian Cancer Foundation and the Brazilian National Cancer Institute evaluated the cost-effectiveness of a unique exam using next-generation sequencing versus other routine tests.

July 22nd 2017

Adjuvant Chemotherapy Reduces Cost, Improves Survival in NSCLC Post-Surgery

Surabhi Dangi-Garimella, PhD

Including adjuvant chemotherapy in the postsurgical treatment plan in patients with non—small cell lung cancer (NSCLC) improves survival and is cost-effective compared with surgical resection alone, according to analysis results presented at the 2017 American Society of Clinical Oncology Annual Meeting.

July 21st 2017

CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference

Kelly Davio

CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2—positive early breast cancer, according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting.

July 21st 2017

Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3

Kelly Davio

Research presented at the 2017 American Society of Clinical Oncology Annual Meeting showed that SB3, a proposed biosimilar to trastuzumab, has comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product based on the breast pathological complete response.

July 21st 2017

Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer

Surabhi Dangi-Garimella, PhD

After switching studies, research in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar, according to results presented at the 2017 Annual Meeting of the American Society of Clinical Oncology.

July 21st 2017

ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation

Surabhi Dangi-Garimella, PhD

The diagnosis of stage I disease increased for female breast cancer, colorectal cancer, and lung cancer following implementation of the Affordable Care Act (ACA), according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago.

July 21st 2017

This Week in Managed Care: July 21, 2017

This week, the top managed care stories included more twists in Senate Republicans' efforts to repeal the Affordable Care Act; a Medicare fraud sweep targeted opioid distribution; and the CDC reported 30 million Americans now have diabetes.

July 21st 2017

Social Interaction Among Patients During Chemotherapy Affects Treatment Response

Alison Rodriguez

Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.

July 21st 2017

Examining How Online Patient-Reported Outcomes Make a Difference in Cancer Care

Christina Mattina

In a webinar hosted by Carevive, researcher Ethan Basch, MD, MSc, discussed the findings of his recent study linking electronic patient-reported outcomes (PROs) to better survival outcomes for patients with cancer.

July 20th 2017

Do We Have Adequate Surveillance in Cancer Care?

Surabhi Dangi-Garimella, PhD

A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology led by Katherine Van Loon, MD, MPH, examined retrospective surveillance data in 3 cancers: non—small cell lung cancer, head and neck cancer, and colorectal cancer.

July 20th 2017

MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges

Surabhi Dangi-Garimella, PhD

At the 2017 American Society of Clinical Oncology Annual Meeting, oncologists heard from fellow experts on the best way to navigate the daunting challenge of payment reform.

July 20th 2017

Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data

Surabhi Dangi-Garimella, PhD

A kickoff session on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago turned in to a lively discussion on ensuring that the data used to inform patient care and create healthcare policies hold value, which could entail foraging real-world data captured in health records.

July 20th 2017

Web-Based Patient Reporting of Symptoms Shown to Improve Survival in Patients With Metastatic Solid Tumors

AJMC Staff

According to outcome results presented at a plenary session at the 2017 American Society of Clinical Oncology Annual Meeting, patients receiving routine outpatient chemotherapy for metastatic solid tumors who self-reported 12 common symptoms via tablet computers experienced an overall survival benefit over those who received usual care.

July 20th 2017

Ibrutinib vs No Consolidation Are Being Compared Following Autologous HSCT in IRONCLAD Trial

AJMC Staff

A poster session at the 2017 American Society of Clinical Oncology Annual Meeting presented the trial details of IRONCLAD, a randomized phase 3 study of ibrutinib versus no consolidation following autologous hematopoietic stem cell transplantation for activated-B-cell subtype relapsed diffuse large B-cell lymphoma.

July 20th 2017

Study Queries Cost—Quality Tradeoff in Narrow Oncology Provider Networks

Surabhi Dangi-Garimella, PhD

Researchers at the University of Pennsylvania have recognized that narrow provider networks are quite likely to exclude National Cancer Institute—Designated Cancer Centers or National Comprehensive Cancer Network Cancer Centers, which could prevent patient access to high-quality cancer care.

July 20th 2017

ASCO Outlines Solutions for More Affordable Cancer Drugs

Christina Mattina

In a recently released position statement, the American Society of Clinical Oncology (ASCO) has outlined a pathway that would address the rising costs of cancer drugs in the United States.

July 19th 2017

Nivolumab, Alone or With Ipilimumab, Met the Disease Control Rate in Malignant Pleural Mesothelioma

AJMC Staff

In a late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting, researchers presented an interim analysis of a randomized phase 2 trial of second- or third-line nivolumab, with or without ipilimumab, in patients with second- or third-line malignant pleural mesothelioma.

July 19th 2017

Three Months of Oxaliplatin-Based Adjuvant Therapy Noninferior to 6 Months in Stage III Colon Cancer

AJMC Staff

The International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration found evidence to support the noninferiority of 3 versus 6 months oxaliplatin-based adjuvant therapy for capecitabine plus oxaliplatin for patients with stage III colon cancer.

July 19th 2017

Fas Biomarker Can Predict Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma

AJMC Staff

In a study performed by the Grupo EspaÃ±ol de InvestigaciÃ³n en Sarcomas, Fas biomarker detection showed value in predicting progression-free and overall survival after trabectedin administration to patients with advanced soft tissue sarcoma.

July 19th 2017

HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults

Surabhi Dangi-Garimella, PhD

The incidence of human papilloma virus (HPV)-positive oropharyngeal cancer can be reduced with a prophylactic vaccine, according to a collaborative study that was presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago.

...

67 68 69 70 71 72 73 74 75

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions